Why 300+ Brand-Name Drugs Are Getting More Expensive in 2026

Every January, pharmaceutical companies reset their price lists, and 2026 has brought one of the largest waves of increases in recent years. Drugmakers have raised list prices on more than 300 brand name medications in the United States, up from roughly 250 drugs at the same point in 2025. For patients managing chronic illness, cancer treatment, or routine vaccinations, this means higher out-of-pocket costs even before insurance is factored in.

Here is what is actually happening, which drugs are affected, and what you can do about it.

Why Are 300+ Drugs Getting More Expensive in 2026

According to healthcare research firm 3 Axis Advisors, drugmakers planned increases on at least 350 branded medications heading into 2026, up from more than 250 drugs the year before. The median hike sits around 4 percent, which is higher than the recent US inflation rate of roughly 2.7 percent. A 4 percent increase might sound modest, but it becomes painful when applied to already expensive specialty medications that people rely on every month.

A few forces are driving this trend:

Spreading smaller increases across more drugs instead of taking a few large double digit hikes, partly in response to political and public pressure.
Patent protections that block generic or biosimilar competition for years after a drug launches, giving manufacturers pricing power with little pushback.
List price versus net price: the price a manufacturer sets publicly does not reflect rebates and discounts negotiated with insurers, but it still determines what uninsured patients or those with high deductibles pay at the pharmacy counter.
Overall growth in health spending, with prescription drugs making up a large and growing share of total healthcare costs in 2026.

Not every price moved upward. Drugmakers also cut prices on a small number of drugs. Boehringer Ingelheim’s diabetes medication Jardiance dropped by more than 40 percent, and Eliquis fell by around 43 percent, both following Medicare price negotiations for drugs used by adults 65 and older. These cuts show that targeted policy action can bring costs down, but they remain the exception rather than the rule.

Which Types of Medications Are Most Affected

The 300+ drug list spans nearly every major treatment category:

Cancer treatments: Blockbuster oncology drugs like Pfizer’s Ibrance are on the list, and even a modest increase can add thousands of dollars a year for people in active treatment.
Vaccines: COVID-19 vaccines such as Comirnaty, along with RSV and shingles vaccines, face price hikes that affect adults needing boosters or catch-up doses.
COVID antivirals: Paxlovid, used to lower hospitalization risk in high-risk patients, is included in this year’s increases.
Chronic disease drugs: Diabetes, heart failure, and respiratory medications are also seeing adjustments, often for patients already managing multiple prescriptions.

Pfizer raised prices on around 80 different drugs to start the year, while GSK increased prices on roughly 20 drugs and vaccines, with individual hikes ranging from 2 percent to nearly 9 percent.

Specific Drugs Patients Should Watch in 2026

Drug	Primary Use	Why the 2026 Price Change Matters
Ibrance	Breast cancer	A widely used cancer therapy; mid single digit increases can add thousands of dollars a year for patients in long treatment.
Paxlovid	COVID-19 antiviral	Higher list prices raise costs for high-risk patients, especially as public health coverage for COVID treatment continues to shrink.
Comirnaty	COVID-19 vaccine	Facing a reported price increase that raises out-of-pocket costs for booster doses.
Cosentyx	Psoriasis, arthritis	Rose by about 6.3 percent in 2026, adding meaningful cost for patients on biologic therapy.
Stelara	Crohn's disease, psoriasis	Increased by about 5 percent, affecting patients who depend on this biologic for chronic conditions.
Entresto	Chronic heart failure	A long term therapy where price hikes place real strain on retirees and patients on fixed incomes.
Nurtec	Migraine	One of the most common migraine treatments, with price increases adding up for patients who need it regularly.

What Patients Can Do If Their Medication Is on the List

You do have options, even as list prices climb. A few practical steps can help:

Review your plan’s 2026 formulary to check whether your medication has moved to a higher cost sharing tier.
Ask your doctor or pharmacist about generic or biosimilar alternatives that may treat your condition at a lower cost.
Compare pharmacy cash prices, since prices for the same brand name drug can vary significantly between pharmacies.
Look into manufacturer or nonprofit patient assistance programs, many of which offer free or reduced cost medication based on income eligibility.

Researching and applying to each assistance program individually is often the hardest part. This is where a prescription assistance company like affordmyprescriptions can help. Instead of navigating dozens of separate manufacturer programs, income requirements, and renewal deadlines on your own, affordmyprescriptions works to match patients with the assistance programs they qualify for and manages the paperwork on their behalf, so brand name medications stay within reach even as list prices continue to rise.

Rising brand name drug prices in 2026 are not a one time event. They follow a pattern that has repeated for years, even alongside high profile pricing deals and political pressure to bring costs down. Reviewing your plan’s formulary, asking about lower cost alternatives, and exploring patient assistance programs remain the most effective ways to manage the impact on your budget.

You should not have to choose between your health and your finances. If rising prescription costs are putting pressure on your budget, reach out to affordmyprescriptions today to find out how much you could save on your brand name medications.